JP2013523884A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523884A5
JP2013523884A5 JP2013504972A JP2013504972A JP2013523884A5 JP 2013523884 A5 JP2013523884 A5 JP 2013523884A5 JP 2013504972 A JP2013504972 A JP 2013504972A JP 2013504972 A JP2013504972 A JP 2013504972A JP 2013523884 A5 JP2013523884 A5 JP 2013523884A5
Authority
JP
Japan
Prior art keywords
pyrazol
alkyl
imidazo
pyrimidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013504972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/031896 external-priority patent/WO2011130146A1/en
Publication of JP2013523884A publication Critical patent/JP2013523884A/ja
Publication of JP2013523884A5 publication Critical patent/JP2013523884A5/ja
Ceased legal-status Critical Current

Links

JP2013504972A 2010-04-14 2011-04-11 JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン Ceased JP2013523884A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14
US61/324,186 2010-04-14
PCT/US2011/031896 WO2011130146A1 (en) 2010-04-14 2011-04-11 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015128369A Division JP2015205905A (ja) 2010-04-14 2015-06-26 JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン

Publications (2)

Publication Number Publication Date
JP2013523884A JP2013523884A (ja) 2013-06-17
JP2013523884A5 true JP2013523884A5 (https=) 2014-05-22

Family

ID=43984073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013504972A Ceased JP2013523884A (ja) 2010-04-14 2011-04-11 JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン
JP2015128369A Pending JP2015205905A (ja) 2010-04-14 2015-06-26 JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015128369A Pending JP2015205905A (ja) 2010-04-14 2015-06-26 JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン

Country Status (21)

Country Link
US (1) US8962596B2 (https=)
EP (1) EP2558468B1 (https=)
JP (2) JP2013523884A (https=)
KR (1) KR20130094710A (https=)
CN (1) CN102985424B (https=)
AR (1) AR081075A1 (https=)
AU (1) AU2011240808B2 (https=)
CA (1) CA2796388A1 (https=)
CL (1) CL2012002882A1 (https=)
CO (1) CO6630187A2 (https=)
CR (1) CR20120572A (https=)
MX (1) MX2012011941A (https=)
NZ (1) NZ603446A (https=)
PH (1) PH12012502046A1 (https=)
RU (1) RU2012148246A (https=)
SG (1) SG184870A1 (https=)
TW (1) TWI494314B (https=)
UA (1) UA109131C2 (https=)
UY (1) UY33328A (https=)
WO (1) WO2011130146A1 (https=)
ZA (1) ZA201208544B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
MX2014005565A (es) * 2011-11-07 2014-05-30 Vertex Pharma Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104884455B (zh) 2012-10-24 2017-09-12 百时美施贵宝公司 丙型肝炎病毒抑制剂
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
JPWO2014157569A1 (ja) * 2013-03-28 2017-02-16 武田薬品工業株式会社 複素環化合物
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
CN107278203B (zh) 2014-12-05 2020-05-19 阵列生物制药公司 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
EA036122B1 (ru) 2015-01-20 2020-09-30 Уси Форчун Фармасьютикал Ко., Лтд Ингибитор jak
AU2016254385B2 (en) * 2015-04-29 2018-05-10 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitors
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
KR102081272B1 (ko) 2015-05-29 2020-02-25 우시 포춘 파마슈티컬 컴퍼니 리미티드 Janus 키나아제 억제제
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
CN106905322B (zh) * 2016-01-26 2019-10-15 杭州华东医药集团新药研究院有限公司 吡咯嘧啶五元氮杂环衍生物及其应用
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
CA3055233C (en) 2017-01-23 2022-08-09 Shanghai Longwood Biopharmaceuticals Co., Ltd. Jak kinase inhibitor and preparation method and use thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
WO2019034973A1 (en) * 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR102925957B1 (ko) 2018-02-16 2026-02-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
CN112771047A (zh) * 2018-09-27 2021-05-07 重庆复创医药研究有限公司 作为RET激酶抑制剂的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
US12404275B2 (en) 2019-04-12 2025-09-02 Primegene (Beijing) Co., Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
MX2022015221A (es) 2020-06-02 2023-03-08 Incyte Corp Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця
KR20240103022A (ko) * 2021-11-12 2024-07-03 소테르 바이오파마 피티이. 리미티드 피라졸로 융합 고리 화합물 및 이의 용도
JP2025515466A (ja) * 2022-04-25 2025-05-15 イーライ リリー アンド カンパニー Fgfr2阻害剤化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG10202003901UA (en) * 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
RS54510B1 (sr) * 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造jak抑制劑之方法及相關中間化合物

Similar Documents

Publication Publication Date Title
JP2013523884A5 (https=)
TWI855070B (zh) Fgfr抑制劑及其使用方法
TWI494314B (zh) 5,7-取代的-咪唑并[1,2-c]嘧啶
JP6385954B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
AU2006326548B2 (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JP5976826B2 (ja) Btk活性阻害剤としての8−フルオロフタラジン−1(2h)−オン化合物
TW202130638A (zh) 2-甲基-氮-喹唑啉
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
EP3630770A1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use
WO2014191894A1 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
JP2019535689A5 (https=)
CN105209460A (zh) 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
KR20160003328A (ko) Btk 활성의 억제제로서의 헤테로아릴 피리돈 및 아자-피리돈 화합물
JP2016525092A5 (https=)
CN105732637B (zh) 杂芳化合物及其在药物中的应用
JP2014511355A5 (https=)
JP2024023699A (ja) 環式化合物およびその使用方法
RU2013136778A (ru) Ингибиторы гистондезацетилазы, композиции и способы их применения
JP2020526549A5 (https=)
JP2021523177A5 (https=)
TW201113286A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP2021518379A5 (https=)
JP2013518823A5 (https=)